Clinical Opportunity

Needed: Dogs Diagnosed with Splenic Hemangiosarcoma

Integrated Chinese Medicine Holdings Ltd. is sponsoring a study at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania entitled:


Effects of I’m-Yunity vs Standard of Care Chemotherapy (Doxorubicin) Alone or in Combination with I’m-Yunity in Dogs with Splenic Hemangiosarcoma


The study objective:

To assess and compare the efficacy and side effects associated with the administration of I’m-Yunity, doxorubicin, or both in combination to positively impact the lifespan and quality of life in dogs diagnosed with splenic hemangiosarcoma.


To be included in this study the following criteria must be met:

  1. Your dog must have confirmation of the diagnosis of splenic hemangiosarcoma by biopsy following splenectomy.
  2. At least 14 days must have passed since the day of surgery.
  3. Your dog must be stable and not likely to require euthanasia within 4 weeks of starting the study as determined by the investigators.
  4. You must be able to administer oral medication (multiple pills and capsules) to your dog.
  5. You must be at least 18 years of age and be able to understand the study requirements.
  6. You must be able to take your dog to the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania located in Philadelphia for all study visits.
  7. Your dog cannot have received any treatment for cancer (chemotherapy or I’m-Yunity).

Owners have the choice between I’m-Yunity or traditional chemotherapy for their dog. Half of the dogs in the chemotherapy group will be randomized to receive I’m-Yunity along with chemotherapy. All study visits, diagnostics and study treatments are free of charge.


If you are interested in having your dog participate in this study, please contact the Veterinary Clinical Investigations Center at 215-573-0302 or vcic@vet.upenn.edu